Maze Therapeutics (NASDAQ:MAZE) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Maze Therapeutics (NASDAQ:MAZE) from a hold rating to a sell rating in a research report released on Saturday morning.

MAZE has been the subject of a number of other reports. Wedbush increased their price target on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. BTIG Research raised their target price on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a report on Friday, September 12th. Guggenheim boosted their price target on shares of Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research report on Monday, September 29th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Maze Therapeutics presently has an average rating of “Buy” and an average target price of $38.57.

Maze Therapeutics Stock Performance

MAZE opened at $33.53 on Friday. The stock has a market capitalization of $1.61 billion and a price-to-earnings ratio of -1.60. The company has a fifty day moving average of $27.90 and a 200 day moving average of $18.30. Maze Therapeutics has a fifty-two week low of $6.71 and a fifty-two week high of $34.73.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Insider Buying and Selling at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $22.37, for a total transaction of $464,043.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. New York State Common Retirement Fund bought a new stake in shares of Maze Therapeutics in the 1st quarter worth about $25,000. CWM LLC purchased a new stake in Maze Therapeutics in the 2nd quarter worth about $28,000. Ameritas Investment Partners Inc. lifted its stake in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Corebridge Financial Inc. bought a new stake in Maze Therapeutics in the first quarter worth about $48,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after buying an additional 1,725 shares during the last quarter.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.